Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2026-09-09 16:02:44 ET · period of report 2026-09-08 · accession 0001193125-26-386431 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-09 16:02 | 2026-09-08 | ARTV | Aslan Fred | CEO, Dir | S - Sale | $10.92 | -23.4K | 1.45M | -2% | -$255.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-08 | S | D | 23,429 | $10.92 | 1,449,765 | D | — | — | (F1) The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026. (F2) The weighted average sale price for the transaction reported was $10.9158, and the range of prices were between $10.72 and $11.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |